🎉 M&A multiples are live!
Check it out!

Clarity Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Clarity Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Clarity Pharmaceuticals Overview

About Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology. It operates as a single segment, which is Development of Radiopharmaceuticals. Geographically, it operates in Australia and the United States.


Founded

2010

HQ

Australia
Employees

n/a

Financials

LTM Revenue $5.1M

LTM EBITDA -$34.1M

EV

$464M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Clarity Pharmaceuticals Financials

Clarity Pharmaceuticals has a last 12-month revenue of $5.1M and a last 12-month EBITDA of -$34.1M.

In the most recent fiscal year, Clarity Pharmaceuticals achieved revenue of n/a and an EBITDA of -$35.5M.

Clarity Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Clarity Pharmaceuticals valuation multiples based on analyst estimates

Clarity Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$22.8M -$35.5M XXX XXX XXX
EBITDA Margin NaN% NaN% XXX XXX XXX
Net Profit -$15.0M -$15.6M XXX XXX XXX
Net Margin NaN% NaN% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Clarity Pharmaceuticals Stock Performance

As of March 17, 2025, Clarity Pharmaceuticals's stock price is AUD 3 (or $2).

Clarity Pharmaceuticals has current market cap of AUD 845M (or $534M), and EV of AUD 734M (or $464M).

See Clarity Pharmaceuticals trading valuation data

Clarity Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$464M $534M XXX XXX XXX XXX $-0.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Clarity Pharmaceuticals Valuation Multiples

As of March 17, 2025, Clarity Pharmaceuticals has market cap of $534M and EV of $464M.

Clarity Pharmaceuticals's trades at 91.3x LTM EV/Revenue multiple, and -13.6x LTM EBITDA.

Analysts estimate Clarity Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Clarity Pharmaceuticals and 10K+ public comps

Clarity Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $464M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -12.7x XXX XXX XXX
P/E -17.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -15.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Clarity Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Clarity Pharmaceuticals Valuation Multiples

Clarity Pharmaceuticals's NTM/LTM revenue growth is 43%

Clarity Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Clarity Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Clarity Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Clarity Pharmaceuticals and other 10K+ public comps

Clarity Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 56% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Clarity Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Medical Imaging & Diagnostics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Clarity Pharmaceuticals M&A and Investment Activity

Clarity Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Clarity Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Clarity Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Clarity Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Clarity Pharmaceuticals

When was Clarity Pharmaceuticals founded? Clarity Pharmaceuticals was founded in 2010.
Where is Clarity Pharmaceuticals headquartered? Clarity Pharmaceuticals is headquartered in Australia.
Who is the CEO of Clarity Pharmaceuticals? Clarity Pharmaceuticals's CEO is Ms. Michelle Parker.
Is Clarity Pharmaceuticals publicy listed? Yes, Clarity Pharmaceuticals is a public company listed on ASX.
What is the stock symbol of Clarity Pharmaceuticals? Clarity Pharmaceuticals trades under CU6 ticker.
When did Clarity Pharmaceuticals go public? Clarity Pharmaceuticals went public in 2021.
Who are competitors of Clarity Pharmaceuticals? Similar companies to Clarity Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Clarity Pharmaceuticals? Clarity Pharmaceuticals's current market cap is $534M
What is the current revenue of Clarity Pharmaceuticals? Clarity Pharmaceuticals's last 12-month revenue is $5.1M.
What is the current EBITDA of Clarity Pharmaceuticals? Clarity Pharmaceuticals's last 12-month EBITDA is -$34.1M.
What is the current EV/Revenue multiple of Clarity Pharmaceuticals? Current revenue multiple of Clarity Pharmaceuticals is 91.3x.
What is the current EV/EBITDA multiple of Clarity Pharmaceuticals? Current EBITDA multiple of Clarity Pharmaceuticals is -13.6x.
Is Clarity Pharmaceuticals profitable? Yes, Clarity Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.